Infectocortikrupp (Prednisolone Acetate)

Prednisolone acetate binds to glucocorticoid receptors inside cells, altering gene expression to suppress the production of inflammatory cytokines and chemokines. This reduces leukocyte infiltration, vascular permeability, and overall inflammatory response, providing potent anti‑inflammatory and immunosuppressive effects at the site of administration.

The specific dose and frequency of Infectocortikrupp are determined by the prescribing clinician based on the severity of the condition, patient age, and response to therapy. Healthcare providers tailor the regimen to achieve optimal therapeutic benefit while minimizing potential risks.

Safety data for rectal prednisolone acetate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Clinicians typically evaluate each case individually and may consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Infectocortikrupp (prednisolone acetate) offers a higher glucocorticoid potency than rectal hydrocortisone preparations, allowing effective inflammation control at lower doses. Compared with budesonide suppositories, it may have a longer duration of action but shares similar safety considerations, such as the risk of systemic absorption with prolonged use.

Infectocortikrupp should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity, which could affect its stability.

The medication is supplied as a rectal formulation, typically a suppository or enema. It is inserted into the rectum according to the prescriber's instructions, usually after bowel movements and before bedtime, to maximize local absorption and minimize leakage.

Serious risks include adrenal suppression, severe systemic infections, hyperglycemia, osteoporosis with long‑term use, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of infection, abnormal blood sugar levels, and any unexpected systemic effects, especially during extended therapy.

Infectocortikrupp is contraindicated in patients with known hypersensitivity to prednisolone acetate or any component of the formulation, and in those with uncontrolled systemic infections. Caution is also advised for individuals with uncontrolled diabetes, severe hypertension, or a history of peptic ulcer disease.